HARRIGAN EDMUND — SEC insider filings
SEC reporting owner CIK 1177917. 43 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 43 filings on record, filed 2020-08-14 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 6,000 shares, $24,720 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 10,000 shares, $833,200 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
- Largest priced transaction: sale of 10,000 shares @ $83.32 ($833,200) in Karuna Therapeutics, Inc., filed 2020-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Karuna Therapeutics, Inc. (KRTX) | Director | 1 | — | 1 leg · 10,000 sh · $833,200 | — |
| PhaseBio Pharmaceuticals Inc (PHAS) | Director | 4 | 1 leg · 6,000 sh · $24,720 | — | 5 |
| INCYTE CORP (INCY) | Director | 32 | — | — | 38 |
| ACADIA PHARMACEUTICALS INC (ACAD) | Director | 6 | — | — | 24 |
Insider filings — HARRIGAN EDMUND
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 206 @ $121.35 | EDGAR |
| 2026-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 255 @ $113.36 | EDGAR |
| 2026-06-10 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 269 @ $94.12 | EDGAR |
| 2026-01-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 245 @ $98.77 | EDGAR |
| 2025-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 289 @ $84.81 | EDGAR |
| 2025-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 367 @ $68.10 | EDGAR |
| 2025-06-12 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,518 @ $0 · Grant/award (A): 9,216 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 363 @ $60.55 | EDGAR |
| 2025-01-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 339 @ $69.07 | EDGAR |
| 2024-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 378 @ $66.10 | EDGAR |
| 2024-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 409 @ $60.62 | EDGAR |
| 2024-06-14 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,830 @ $0 · Grant/award (A): 12,517 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 6,652 · Option exercise (M): 6,652 (derivative) @ $0 · Grant/award (A): 15,959 (derivative) @ $0 · Grant/award (A): 9,387 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 413 @ $56.97 | EDGAR |
| 2024-01-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 423 @ $62.79 | EDGAR |
| 2023-10-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 389 @ $57.77 | EDGAR |
| 2023-07-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 390 @ $62.25 | EDGAR |
| 2023-06-16 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,505 @ $0 · Grant/award (A): 11,294 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 3,059 · Option exercise (M): 6,391 · Option exercise (M): 8,552 · Option exercise (M): 3,059 (derivative) @ $0 · Option exercise (M): 6,391 (derivative) @ $0 · Option exercise (M): 8,552 (derivative) @ $0 · +2 more | EDGAR |
| 2023-05-19 | 4 | PhaseBio Pharmaceuticals Inc (PHAS) | Option exercise (M): 3,750 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 326 @ $72.27 | EDGAR |
| 2023-01-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 302 @ $80.32 | EDGAR |
| 2022-10-20 | 4 | INCYTE CORP (INCY) | Grant/award (A): 165 @ $69.59 | EDGAR |
| 2022-10-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 250 @ $66.64 | EDGAR |
| 2022-07-01 | 4 | INCYTE CORP (INCY) | Grant/award (A): 236 @ $75.97 | EDGAR |
| 2022-06-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,144 @ $0 · Grant/award (A): 9,124 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Grant/award (A): 14,368 (derivative) @ $0 · Grant/award (A): 8,552 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | PhaseBio Pharmaceuticals Inc (PHAS) | Grant/award (A): 17,500 (derivative) @ $0 · Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 240 @ $79.42 | EDGAR |
| 2022-01-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 253 @ $73.40 | EDGAR |
| 2021-10-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 237 @ $68.78 | EDGAR |
| 2021-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 208 @ $84.13 | EDGAR |
| 2021-06-24 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Grant/award (A): 11,637 (derivative) @ $0 · Grant/award (A): 6,391 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | PhaseBio Pharmaceuticals Inc (PHAS) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,923 @ $0 · Grant/award (A): 8,010 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | INCYTE CORP (INCY) | Grant/award (A): 219 @ $81.27 | EDGAR |
| 2021-01-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 207 @ $86.98 | EDGAR |
| 2020-12-04 | 4 | PhaseBio Pharmaceuticals Inc (PHAS) | Purchase (P): 6,000 @ $4.12 | EDGAR |
| 2020-10-01 | 4 | INCYTE CORP (INCY) | Grant/award (A): 187 @ $89.74 | EDGAR |
| 2020-08-14 | 4 | Karuna Therapeutics, Inc. (KRTX) | Sale (S): 10,000 @ $83.32 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1177917 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs